Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 435 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lymph Clear all
Terminated No phase listed Observational

Characterizing the Effect of Dopamine on Markers of Lymph Re-circulation in Fontan-associated Protein-losing Enteropathy

NCT03322345
View directory record Official record
Conditions
Dopamine, Protein-Losing Enteropathies, Lymphatic System, Lymph, Catecholamine, Single-ventricle, Congenital Heart Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
3 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 19, 2026, 1:35 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood

NCT03898973
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent inactivated influenza vaccine (IIV)
Biological
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 19, 2026, 1:35 AM EDT
Completed Not applicable Interventional

The Cellularity Yield of Three Different 22-gauge FNA Needles

NCT01916421
View directory record Official record
Conditions
Pancreatic or Peripancreatic Lesions, Lesions in the Esophagus, Stomach, Duodenum or Rectum, Mediastinal ( Chest) Masses, Enlarged Lymph Nodes
Interventions
Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)
Procedure
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 88 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 19, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease

NCT00841789
View directory record Official record
Conditions
Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Michael Portman
Other
Eligibility
2 Months to 20 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
7
States / cities
New Hyde Park, New York • New York, New York • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 19, 2026, 1:35 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
88
States / cities
Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 1:35 AM EDT
Active, not recruiting Phase 3 Interventional

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

NCT01223248
View directory record Official record
Conditions
Melanoma, Ovarian Cancer, Sarcoma, Bone, CNS-Spinal CD/MEMBR, NOS, Lymph Nodes, Soft Tissue
Interventions
IGIMRT using a single dose of 24 Gy, IGIMRT 27 Gy in 3 fractions
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 19, 2026, 1:35 AM EDT
Recruiting No phase listed Observational

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

NCT06689956
View directory record Official record
Conditions
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 19, 2026, 1:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

NCT02509507
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors
Interventions
Talimogene Laherparepvec, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
9
States / cities
Scottsdale, Arizona • Santa Monica, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 19, 2026, 1:35 AM EDT
Not listed Not applicable Interventional

Improved Method of Detecting Cancer Metastases

NCT02368067
View directory record Official record
Conditions
Endometrial Carcinoma
Interventions
Standard of Care Sentinal Node Dye, Study Sentinal Node Dye
Procedure
Lead sponsor
Southeastern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 19, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

NCT00790036
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Everolimus, Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
34
States / cities
Chandler, Arizona • Fayetteville, Arkansas • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 19, 2026, 1:35 AM EDT
Active, not recruiting Not applicable Interventional Results available

PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer

NCT01737619
View directory record Official record
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Grade 3 Endometrial Endometrioid Adenocarcinoma, Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions
Computed Tomography, Indocyanine Green Solution, Laboratory Biomarker Analysis, Lymph Node Mapping, Lymphadenectomy, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
7
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 1:35 AM EDT
Completed No phase listed Observational

Role of Axumin PET Scan in Germ Cell Tumor

NCT03426865
View directory record Official record
Conditions
Testis Cancer, Germ Cell Tumor, Testicular Cancer, Germ Cell Tumor of Testis, Germ Cell Tumor, Testicular, Childhood, Testicular Neoplasms, Testicular Germ Cell Tumor, Testicular Yolk Sac Tumor, Testicular Choriocarcinoma, Testicular Diseases, Germ Cell Cancer Metastatic, Germ Cell Neoplasm of Retroperitoneum, Germ Cell Cancer, Nos
Interventions
Axumin PET scan
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 19, 2026, 1:35 AM EDT
Recruiting Not applicable Interventional

LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)

NCT04606030
View directory record Official record
Conditions
Lymphedema, Edema
Interventions
BioBridge® Collagen Matrix, Vascularized Lymph Node Transfer (VLNT)
Device · Procedure
Lead sponsor
Fibralign Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 19, 2026, 1:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HIPEC After Radical Cystectomy for High Risk Bladder Cancer

NCT03514888
View directory record Official record
Conditions
Invasive Bladder Cancer
Interventions
HIPEC
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 19, 2026, 1:35 AM EDT
Recruiting Early Phase 1 Interventional

LYmph Node eXamination in Cat Allergen Immunotherapy

NCT07447869
View directory record Official record
Conditions
Allergy
Interventions
Intradermal cat allergen challenge
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 19, 2026, 1:35 AM EDT
Completed No phase listed Observational

Lymph Node Assessment Using Simultaneous 18F-FDG-PET and MRI

NCT02180308
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
PET/MRI
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 19, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Results available

Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer

NCT03733210
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Head and Neck
Interventions
Panitumumab-IRDye800, 89-Zirconium (Zr-89) Panitumumab, Pinpoint IR IR9000 fluorescence imaging system (FIS), SPY-PHI IR9000 fluorescence imaging system (FIS), Explorer Air camera, PDE-NEO II camera, FIS-00 fluorescence imaging system (FIS), Da Vinci Firefly Imaging System, IGP-ELVIS-v4 Macroscopic Specimen Imager, Vevo 3100 LAZR-X, Pearl Triology Imaging System, Odyssey CLx Imaging System, Leica fluorescence microscope
Drug · Device
Lead sponsor
Andrei Iagaru
Other
Eligibility
19 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 19, 2026, 1:35 AM EDT
Completed Not applicable Interventional

Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Treatment of Colorectal Cancer

NCT00005640
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Preoperative Endoscopy, Technetium Tc 99m Sulfur Colloid, Gamma Probe, Biopsy of Sentinel Lymph Nodes
Procedure · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 19, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer

NCT03796767
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Oligometastasis, Prostate Adenocarcinoma, PSA Failure
Interventions
Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Metastasectomy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Procedure · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 19, 2026, 1:35 AM EDT
Active, not recruiting Not applicable Interventional

Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

NCT05019976
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Hodgkin Lymphoma, Lymphoma
Interventions
Radiation - Dose Level 0, Radiation - Dose Level 1, Radiation - Dose Level 2, Radiation - Dose Level 3, Radiation - Dose Level 4
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 19, 2026, 1:35 AM EDT
Withdrawn Not applicable Interventional

Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients

NCT02112240
View directory record Official record
Conditions
Rectal Cancer
Interventions
Intraoperative Mobile Gamma Camera imaging, Endoscopic injection of 99mTc-sulfur colloid, Endoscopic injections of Spot, Preoperative flexible sigmoidoscopy, SPECT/CT
Other · Drug · Procedure + 1 more
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 19, 2026, 1:35 AM EDT
Terminated No phase listed Observational

Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection

NCT05236387
View directory record Official record
Conditions
Breast Cancer
Interventions
99m Tc-TM
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 19, 2026, 1:35 AM EDT
Completed Not applicable Interventional

Enhancing Management of Chronic Pain and Symptoms Among Women Treated for Breast Cancer (Lymph-Flow)

NCT02462226
View directory record Official record
Conditions
Breast Cancer, Pain, Lymphedema
Interventions
The-Optimal-Lymph-Flow, Arm Precaution
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 89 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 19, 2026, 1:35 AM EDT
Suspended Phase 2 Interventional

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

NCT06868238
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Magtrace
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 1:35 AM EDT